Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

Denis Gaucher,1,2,3 René Therrien,1,2,3 Nadia Kettaf,1,2,3 Bastian R. Angermann,1,2 Geneviève Boucher,1 Abdelali Filali-Mouhim,1 Janice M. Moser,4 Riyaz S. Mehta,4 Donald R. Drake III,4 Erika Castro,5,6 Rama Akondy,7 Aline Rinfret,8,9 Bader Yassine-Diab,1,2,3 Elia A. Said,1,2,3 Younes Chouikh,1,2,3 Mark J. Cameron,10 Robert Clum,10 David Kelvin,10 Roland Somogyi,11 Larry D. Greller,11 Robert S. Balderas,12 Peter Wilkinson,1 Giuseppe Pantaleo,5 Jim Tartaglia,13 Elias K. Haddad,1,2,3,14 and Rafick-Pierre Sékaly1,2,3,14

Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.

© 2008 Gaucher et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/.

Correspondence
Rafick-Pierre Sékaly: rafig-pierre.sekaly@umontreal.ca

Abbreviations used: CBA, cyto-metric bead assay; ICA, independent component analysis; MIMIC, modular immune in vitro construct; qPCR, quantitative real-time PCR; TLR, Toll-like receptor; YF, yellow fever; YF17D, YF vaccine 17D.

N. Kettaf and B. R. Angermann and E. K. Haddad and R.-P. Sékaly contributed equally to this paper.

Supplemental material can be found at:
http://doi.org/10.1084/jem.20082292

The Rockefeller University Press $30.00
www.jem.org/cgi/doi/10.1084/jem.20082292
Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. Moreover, there is a paucity of information regarding the qualitative and quantitative properties of emerging protective responses in vivo in humans, and this has been a major impediment to vaccine development (1). Although humoral immunity is clearly the dominant correlate of protection for vaccines against bacterial pathogens (2), viruses or tumors require a more complex immune response with contributions from both T and B cells (3). Innate immunity, which is known to shape the development of adaptive immune responses, could also contribute to vaccine-mediated protection through mechanisms yet to be defined.

Developed empirically in the 1930s, the live attenuated yellow fever (YF) vaccine 17D (YF17D) is considered one of the most successful vaccines ever made (4); a single dose can confer protective immunity for up to 35 yr, in almost all vaccinated individuals. The humoral immune response to 17D is generally considered the main mediator of protection against a challenge infection with wild-type YF virus. Passive immunization in monkeys (5) and mice (6) has mediated protection against YF infection. Although the humoral response inarguably plays a central role, we cannot rule out the contribution of the other arms of the immune system, cellular and innate immunity, which is known to shape the development of adaptive immune responses, could also contribute to vaccine-mediated protection in humans by vaccination with YF17D, in an effort to unravel the correlates of protection conferred by one of the most potent vaccines ever generated.

RESULTS

Vaccination with YF17D rapidly and transiently induces modulation of genes associated with multiple pathways

RNA samples obtained from whole blood of 15 YF17D-vaccinated individuals (from the Montreal cohort) on the day of vaccination (day 0) and at several time points after vaccination (day 3, 7, 10, 14, 28, and 60) were amplified and hybridized onto Illumina chips and analyzed. Expression profiles of 594 genes (Supplemental document 1, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1) were found to change significantly between day 0 and any time point after vaccination (with P < 0.05 and fold change less than −1.3 or >1.3). The peak of modulation of gene expression, as shown by heat map representation (Fig. 1 a) and principal component analysis (Fig. 1 b), primarily occurred at days 3 and 7 after vaccination, whereas a limited number of significant genes were modulated in response to vaccination at day 10 after vaccination or beyond.

Independent component analysis (ICA), followed by gene set enrichment, identified transcription factors with predicted (11) target genes showing a specific modulation after YF17D vaccination (Fig. 2 and Fig. S1, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1). With this approach, three major nodes of transcriptional regulation immune in vitro construct [MIMIC co-culture system], to identify the emerging protective immune response induced in humans by vaccination with YF17D, to unravel the correlates of protection conferred by one of the most potent vaccines ever generated.

Figure 1. Vaccination with YF17D induces early gene modulation.

Global view of gene modulation in total blood cells after YF17D vaccination, as analyzed by gene array on the Montreal cohort (n = 9–15, depending on the time point). Heat map representation (a) and PCA (b) using the significantly modulated genes, in at least one comparison versus day 0.
Genes associated with B cell activation (BANK1, CD19, IGJ, TNFRSF13B, and TNFRSF17; Fig. 3e) were also modulated. Other genes also involved in the induction of an immune response, such as TAP1 and TAP2, which encode proteins involved in antigen processing and presentation (12, 13), and SOCS1, which encodes a protein involved in a negative feedback loop meant to attenuate cytokine signaling (14), were up-regulated as well (Supplemental document 1). Strikingly, we observed that 43 genes encoding ribosomal proteins were down-regulated in PBMCs early after vaccination with YF17D (Supplemental document 1), confirming the findings of a previous study (15). Collectively, these results reveal that vaccination with YF17D stimulated a rapid and transient modulation of several genes of immunological importance, which allowed us to infer a signature of gene modulation by ICA.

Two levels of validation were performed to confirm the results observed in this initial trial; the first validation was achieved by performing quantitative real-time PCR (qPCR) on RNA from 7 volunteers from the Montreal cohort for 43 genes selected to represent 8 of the identified transcription nodes and some of their target genes. As shown in Fig. S2 (available at http://www.jem.org/cgi/content/full/jem.20082292/DC1), we could observe a highly significant correlation between the results obtained by qPCR and those of downstream target genes were found as early as day 3 (IRF7 and STAT1) and day 7 (ETS2). Other nodes of transcription factors (IRF1, IRF8, GATA6, GATA1, TAL1, FOXO3a, E2F4, E2F1, LMO2, SRF, and CEBPB) also controlled the expression of several of the genes and pathways that were modulated in the first week after immunization.

Many of the genes that were modulated by YF17D vaccination could be classified under different functional categories, based on published literature (Fig. 3 and Supplemental document 2, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1). Some Toll-like receptor (TLR)-associated genes (TLR7, MYD88, and IRF7) were also up-regulated, leading to the activation of the IFN pathway, as monitored by the induction of several IFN-induced genes (IFI27, IFI30, G1P2, G1P3, and OAS1-3; Fig. 3a and Supplemental document 1). Components of the complement system (C1QA, C1QB, C3AR1, and SERPING1) were found to be up-regulated in blood cells early after vaccination (Fig. 3b). A few macrophage/DC-associated genes were induced significantly by the vaccine, including CD86 (a marker of DC maturation), CSF1R, MARCO, and IFI16, which are expressed by cells of the monocyte-macrophage lineage (Fig. 3c). NK cell–associated genes (KIR2DL3, KIR2DL4, PRF1, GNLY, and GZMB) were also up-regulated (Fig. 3d).

**Figure 2.** Transcriptional network of differentially expressed genes after YF17D vaccination, as inferred by gene set enrichment. Network representation of inferred transcription factors (11) and predicted target genes that are significantly modulated. Node colors indicate fold change of gene expression between day 0 and 7 in n = 11 volunteers. Rectangular nodes indicate transcription factors identified by gene enrichment; the different shapes indicate genes in the different functional categories of Fig. 3 (a–e). Genes that were subsequently evaluated by RT-PCR are identified by an asterisk. IRF1, IRF8, and genes targeted by IRF1 or IRF8, but no other transcription factors in the figure were removed to increase readability (see Fig. S1 for a complete map). Fig. S1 is available at http://www.jem.org/cgi/content/full/jem.20082292/DC1.
obtained by gene microarray, with coefficients of correlation ranging between 0.78 and 0.96. A detailed analysis of the entire set of genes is represented in Table S1. The second validation was achieved by comparing the aforementioned qPCR dataset for the Montreal cohort to datasets from two other, independent YF17D vaccination trials: the Lausanne cohort (13 volunteers) and the Emory cohort (10 volunteers). The results illustrated in Fig. 4 and in Fig. S3 indicate that most genes that were up-regulated in the Montreal cohort also showed increased expression in the two other independent trials. Conversely, most down-regulated genes in the Montreal cohort also showed decreased levels of expression in the samples obtained from the two other trials. These results demonstrate the proper validation of our gene array data by two different strategies: the use of qPCR and an increase in sample size.

The YF17D vaccine up-regulates IL-1β production

Our gene array results showed that two components of the inflammasome, caspase-1 and -5, were up-regulated at the mRNA level in the Montreal cohort, 3 d after vaccination with YF17D (Fig. 5 a). Two other genes related to IL-1β production and signaling that were modulated by the vaccine are IL-1R2 and -1RN. All of these genes, except for caspase-5, were also similarly modulated in the Lausanne cohort. To functionally validate the microarray data suggesting the activation of the inflammasome by the vaccine, we quantified the secretion of IL-1β, which has been shown to be processed and produced by an active inflammasome assembly (16). The results show that DCs incubated with live or UV-inactivated YF17D showed a marked increased IL-1β secretion (up to ninefold, compared with DCs incubated in medium alone), whereas heat-inactivated YF17D only triggered a modest secretion of the proinflammatory cytokine (Fig. 5 b and Fig. S4, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1). These functional results confirm the gene array data, suggesting that YF17D activates components of the inflammasome complex, and that viral replication is not required for this effect.

YF17D vaccination leads to the proliferation and expansion of several leukocyte subtypes

Given that immunization with YF17D gives rise to the up-regulation of genes associated with different leukocyte populations, we were interested in determining whether the vaccine also induces the proliferation of these cells. To do so, PBMCs from six volunteers, sampled at day 0, 3, 7, 10, 14, and 28 after vaccination, were stained with anti-Ki67 and other specific antibodies to identify, by flow cytometry, different cell subsets that are actively proliferating. The staining/gating strategies and the results are shown in Fig. S5 (a and b, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1), respectively. An increase in frequencies of Ki67+ cells in the CD4+CD8− (2.3-fold increase; P = 0.0049) and the CD4−CD8+ (4.7-fold increase; P = 0.0157) populations occurred within the first 14 d after YF17D vaccination, and then decreased to insignificant levels. The Ki67+ NK cell population...
Vaccination with YF17D induces a broad and persistent YF-specific T cell response

We next assessed the amplitude, breadth, and persistence of the YF17D-specific T cell response. PBMCs sampled at day 60 after vaccination were incubated in the presence of each of 22 YF17D-derived peptide pools (Fig. S6 a, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1), and their proliferation was measured by CFSE labeling. Fig. S6 b describes the cytometry gating strategy used, and the results are shown in Fig. 6 (bar graphs) and Fig. S6 (c and d). Both the CD4+ and CD8+ T cell proliferative responses were highly variable among the vaccinated volunteers. Strong CD4+ responders (notably YF001, 002, 009, 018, and 020) recognized most, if not all, of the peptide pools (>20), whereas weak responders (YF005, 011, and 017) recognized only a few (<5). The CD8+ responses were generally much weaker than those observed in CD4+ T cells, and although only 2 responders recognized 19 of the pools (YF001 and 020), 10 of them recognized <5. Notably, some peptide pools were recognized by more volunteers than others (pools 1, 3, and 17 were recognized by CD4+ T cells of at least 12 volunteers), whereas others were recognized by just a few volunteers (pools 5 and 7 were recognized by CD4+ cells of at most 7 volunteers). Both CD4+ and CD8+ T cell peptide-specific responses were persistent, as memory proliferative responses to the most immunodominant peptide pools were detected as long as 1 yr after immunization (unpublished data). These results show that the breadth of the T cell responses to the YF17D vaccine is highly variable from one vaccinated individual to another, but that those responses are persistent.

The YF17D vaccine induces a mixed Th1/Th2 response that appears early and is persistent

Next, we sought to determine at the protein level the cytokine profiles produced by PBMCs after stimulation with YF17D-derived peptide pools. We used cytometric bead assay (CBA) to assess the levels of the Th1 cytokines IL-2, IFN-γ, and TNF, and the Th2 cytokines IL-4 and -10 secreted by these cells. Fig. 6 shows the results for six selected volunteers (heat maps); a summary of the CBA results for all volunteers and pools tested can be found in Fig. S6 e. In our system, high levels of TNF were detected in several supernatants, whereas the other cytokines were either found in low amounts or not detected. Hence, the qualitative and quantitative features of cytokine production were highly variable; pool 3 stimulated a mixed Th1/Th2 response in volunteer YF001, but triggered only a Th1 response in subjects YF002, 3, 9, and 20, whereas no detectable response to this pool could be seen in YF019. In most volunteers (12 out of 15), both Th1 and Th2 cytokine secretion profiles were induced by YF17D peptide pools. Three volunteers (YF0014, 15, and 16), who were weak responders to the vaccine as measured by T cell proliferation, did not show a mixed Th1/Th2 profile; however, these individuals were still able to mount very good antibody responses (Table S2, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1).

We further demonstrated the emergence of a mixed Th1/Th2 response to the vaccine at the single-cell level using polychromatic flow cytometry. First, we confirmed the Th1 phenotype of antigen-specific CD4+ T cells by stimulating PBMCs from vaccinated volunteers (28 d after vaccination) with immunostimulatory peptide pools, and identifying antigen-specific T cells by the expression of the activation marker CD154 (17, 18) and the production of IL-2 and IFN-γ. As illustrated in Fig. 7 a, 35.2% of CD4+CD154+ cells expressed IL-2 alone, 8.6% expressed IFN-γ alone, and 29.5% expressed both IL-2 and IFN-γ.

To determine if this mixed Th1/Th2 response was persistent, we detected YF17D-specific Th1 and Th2 cells in

Figure 5. YF17D induces expression of genes associated with IL-1β and activates the inflammasome. (a) Heat maps showing the up-regulation of genes encoding inflammasome components and the modulation of other, IL-1β-associated genes. For IL-1R2 and -1RN only probes targeting all transcripts were considered. (b) IL-1β production by monocyte-derived DCs incubated with live (YF), UV-inactivated (UV), or heat-inactivated (HI) YF17D, as determined by ELISA. NI, noninfected cells. This represents the results from one representative of three separate experiments. The results for the two other experiments are shown in Fig. S4. Fig. S4 is available at http://www.jem.org/cgi/content/full/jem.20082292/DC1.
PBMCs sampled at day 365 after vaccination. The cells were stimulated for 6 d with YF17D-derived immunostimulatory peptide pools to increase the frequency of antigen-specific cells, and then restimulated with the same pools for 18 h. The cells were then stained for the activation marker CD154, as well as for surface markers, allowing the discrimination between the Th1 (CXCR3^+CCR4^−) and Th2 (CXCR3^−CCR4^+CCR6^−) phenotypes in central memory T helper cells (19). See Fig. S7 (available at http://www.jem.org/cgi/content/full/jem.20082292/DC1) for the full staining and gating strategies and Fig. 7 b for the results. Although some peptide pools stimulated a mixed Th1/Th2 response in a given volunteer, others either stimulated a Th1, a Th2, or no particular profile. However, both Th1 and Th2 central memory T cells could be detected in all four volunteers tested. Together, these results confirm the polyfunctionality of the immune response induced by YF17D, as we observe not only a strong innate immune response but also a mixed Th1/Th2 response that is persistent.

The transcription factors identified during in vivo YF17D vaccination were also central in an in vitro model of YF17D primary immune response

The MIMIC system is a powerful tool for the in vitro study of the early events taking place in a primary immune response. We used this novel approach to validate the multilineage response to YF17D, particularly the expression of transcription nodes and the secretion of mixed Th1/Th2 cytokines. Blood

Figure 6. YF17D induces a mixed Th1/Th2 response. (a) Day 60 PBMCs were stimulated with the 22 peptide pools and assayed by CFSE labeling for their proliferative response. Bar graphs show data for six selected volunteers, and the dataset for all the volunteers can be found in Fig. S6 (c and d). At 24 h of culture, supernatants were analyzed by CBA to determine the Th1/Th2 cytokine secretion profile in response to each pool. The heat maps represent the data for the same six volunteers. The Th1/Th2 profiles determined this way for all the volunteers and pools are shown in Fig. S6 e. Fig. S6 is available at http://www.jem.org/cgi/content/full/jem.20082292/DC1.
monocyte-derived DCs from YF-naive individuals were pulsed with YF17D virus for 24 h, and then co-cultured for 14 d with autologous CD4+ T cells. The resulting culture superna-

tants were harvested for cytokine quantification, and the cells stained for polychromatic flow cytometry analysis. As shown in Fig. 8 a, DCs pulsed with YF17D virus (live or UV-inacti-
vated) primed a strong antigen-specific response of naive T cells, with up to 4% cells expressing CD154 and IFN-γ in

Figure 7. YF17D vaccination induces specific CD4+ T cells of mixed T helper phenotype. (a) PBMCs from YF17D-vaccinated volun-
tees (day 28 after vaccination) were stimulated with a group of three immunostimulatory YF17D-derived peptides pools, and then stained with antibodies against CD4 (surface) and CD154, IL-2, and IFN-γ (intracel-
lular). The numbers indicate the percentages of cells within the parent population. (b) FACS analysis of PBMCs from day 365 after vaccination. Cells from four volunteers were stimulated (S) for with immunostimula-
tory YF17D peptide pools, and then restimulated (RS) or not with the same peptide pools before staining. The data were analyzed according to the gating strategy shown in Fig. S7, and are expressed as the percentage of central memory CD4+ T cells (CD45RA2CCR7+) that express the marker for recent activation CD154, and that are either Th1 or Th2 in the RS samples, over background (S). Fig. S7 is available at http://www.jem.
.org/cgi/content/full/jem.20082292/DC1.

Figure 8. YF17D elicits robust and diverse primary T helper cell responses in DC/T cell co-cultures. (a and b) Purified T helper cells were mixed with DCs that had been incubated with live or UV-inactivated YF17D. After 14 d, the cells were harvested and evaluated by flow cytometry for cytokine and CD154 expression after a short restimulation with autologous DCs targets that had been left untouched, pulsed with killed YF17D, or infected with live YF17D. All data plots show live CD4+-gated events. These are representative data of experiments done on cells from at least 10 volunteers. (c) Alternatively, the culture supernatants were har-
vested and evaluated by a multiplex cytokine analysis. Data representative of experiments done on cells from two volunteers.
response to live or UV-inactivated YF17D. Similarly, YF17D-pulsed DCs stimulated high numbers of antigen-specific Th2 cells expressing IL-5 and IL-13, upon restimulation with live or inactivated virus (Fig. 8 b). The levels of the cytokines IL-2, IFN-γ, IL-13, IL-5, and IL-10 in the MIMIC co-culture supernatants were measured by multiplex cytokine analysis (Fig. 8 c). When YF17D was used as pulse and recall antigen, the cells produced high levels of all the cytokines measured except IL-10, compared with co-cultures with no recall antigen. Collectively, the results show that the MIMIC system induced a YF17D-specific primary CD4+ T cell response, and furthermore, it allowed us to confirm the induction of a mixed Th1/Th2 immune response by the YF17D vaccine.

Finally, the MIMIC approach was used to independently assess our working hypothesis that the transcriptional nodes induced in whole blood cells after vaccination with YF17D can also be induced in vitro by the vaccine. Co-cultures containing YF17D-pulsed DCs and CD4+ T cells (with or without YF17D as recall antigen) were harvested and total RNA was isolated from the cells. Gene modulation in response to the antigen (day 7 vs. 0) was assessed by microarray analysis. In total, eight nodes of transcriptional regulation of downstream target genes were consistently identified; ETS2, STAT1, IRF1, IRF7, IRF8, GATA1, LMO2, and JUN (Fig. 9). Table S3 (available at http://www.jem.org/cgi/content/full/jem.20082292/DC1) summarizes the transcriptional nodes identified with the Montreal cohort, the Lausanne cohort, and the VaxDesign system. These data demonstrate that the same central nodes of transcription are activated in in vivo vaccination with YF17D and in an in vitro system of primary immune response to the virus.

DISCUSSION

In this study, we have used systems biology and polychromatic flow cytometry to characterize the early immunological processes that are initiated by one of the most potent vaccines ever generated, the YF vaccine YF17D, and which culminate into persistent immunological memory and long-term protection against a challenge infection (20). The vaccine induced a significant modulation of 594 genes in whole blood cells, with the highest number of genes being induced at day 7 after vaccination. ICA and gene set enrichment allowed us to identify several nodes of transcriptional regulation that became induced within the first week after immunization. This early response was highly integrated, as several of the downstream target genes were coordinately regulated by these transcription factors.

Of the identified nodes, IRF7 was prominently involved in this masterswitch regulation. The induction of IRF7 has been shown to mediate innate and adaptive immunity against many viruses, including encephalomyocarditis virus, vesicular stomatitis virus, influenza virus, and Sindbis virus (21, 22), confirming the significance of this gene in mediating protective immunity and in inducing strong innate and adaptive immune responses. It was also recently reported that the YF17D virus activates DCs by triggering their TLR2, 7, 8, and 9 (23). Our data reveal that TLR7 and its downstream adaptor molecule Myd88 are both up-regulated upon vaccination with YF17D. TLR7 is a molecular sensor for single-stranded RNA, such as the nucleic acid found in YF17D and other flaviviruses, and triggering of TLR7 causes the transduction of a signal, via Myd88, to up-regulate expression of inflammatory cytokines such as IL-6, IL-12, and TNF (via NF-κB) and type I IFNs (via IRF7) (22, 24). Type I IFNs in turn enhance the expression of proteins with direct antiviral activity, such as ISG20 and OAS1, 2, and 3, which lead to viral RNA degradation, and MX1, MX2, ADAR, and EIF2AK2, which inhibit viral replication. We are showing that all these genes are up-regulated upon YF17D vaccination.

Figure 9. Consensus transcriptional network of genes differentially expressed on day 7 as compared with day 0. Network representation of inferred transcription factors and predicted target genes that are consistently modulated in at least two out of three datasets, with the third dataset not being contradictory.
Another prominent node of transcription regulation induced by YF17D vaccination is the ETS2 transcription factor. ETS2 is involved in the differentiation and maturation of several immune cell types (25). Its expression is up-regulated in activated and proliferating T cells (26) and ETS2 is involved in IL-12 p40 (Th1) and IL-5 (Th2) gene expression (27, 28). ETS2 obviously plays a key role in the highly integrated response to YF17D, as it enhanced transcription of several downstream genes that play critical roles in the maturation and differentiation of T cells, B cells, NK cells, and macrophages (Fig. 2, Fig. 3, and Fig. S1). Indeed, antigen-presenting cell–specific genes that are targets of ETS2 were up-regulated early after vaccination (MARCO, CD86). The role of ETS2 in the early induction of innate immunity is further demonstrated by the increased expression of NK cell receptors, as well as several cytolytic molecules; KIRDL3, PRF1, and GZMB are known targets of members of the Ets family of transcription factors (25, 29). Moreover, flow cytometry analysis on PBMCs from vaccinated volunteers revealed that YF17D stimulates the proliferation of several leukocyte populations (Fig. S5 b).

Several of the other predicted transcription nodes are likely to play significant roles in the induction of innate and adaptive immunity in response to YF17D. IRF1 mediates the antiviral activity of IFNs, similar to IRF7 (30). IRF1 and IRF8 were found to synergistically activate IL-12 p35 and p40 gene expression in macrophages (31–33). IRF8 also mediates activation of NF-kB upon TLR9 triggering in DCs (34), and IRF8 and LMO2 were both found to be expressed in B cell germinal centers, suggesting a role in the development of the humoral response (35, 36). Moreover, TAL1 may be involved in T cell proliferation and differentiation (37). E2F4 is involved in cell cycle regulation (38), and FOXO3A and E2F1 are mediators of apoptosis (39, 40).

A common feature of these masterswitch genes is that they control the induction of several pathways of the innate immune response, including type I IFNs, but also the inflammasome and complement. The inflammasome is a large protein assembly that includes pyrin- and CARD domain–containing adaptor proteins complexed with cysteine proteinases known as caspases. It mediates the processing and activation of these caspases, and subsequently the cleavage and secretion of the proinflammatory cytokines IL-1β and -18 (41). Activation of the inflammasome has been recently shown to be induced by adeno-viruses (42), and to be a key event for the successful adjuvant effect of alum, one of the only two adjuvants licensed to be used in humans (43). Our gene array results demonstrate that two components of the inflammasome, caspase-1 and -5, were up-regulated after YF17D vaccination, in volunteers from the Montreal cohort, whereas only caspase-1 is up-regulated in volunteers from the Lausanne cohort (Fig. 5 a). There are different kinds of inflammasomes, each containing a specific combination of inflammatory caspases and adaptor molecules (44). Hence, NALP1 inflammasomes contain ASC, NALP1, caspase-1, and caspase-5, whereas NALP3 inflammasomes contain ASC, NALP3, and caspase-1 (no caspase-5).

It is possible that NALP1 inflammasomes were not induced in volunteers from the Lausanne cohort, whereas NALP3 inflammasomes were induced in both cohorts. Interestingly, our gene array data also show a modulation of genes that are involved in IL-1β signaling, IL-1R2 and IL-1RN. IL-1R2, which is a decoy receptor that competes with the binding of IL-1β to its receptor (45), is down-regulated, further confirming increased inflammasome activities and IL-1β processing and secretion after immunization with YF17D. The gene encoding IL-1RN, a cytokine that is an IL-1R antagonist, is up-regulated upon vaccination; this increase could be part of a negative feedback loop or could be caused by the up-regulation of STAT1 and STAT2, two transcription factors that induce IL-1RN up-regulation (46, 47). Activation of the inflammasome by YF17D was confirmed at the protein level by incubating immature DCs with the virus and assessing their IL-1β secretion. Representative results of ex vivo experiments performed on cells from a minimum of three individuals are shown in Fig. 5 b and Fig. S4, and clearly validate the gene expression data, as we could observe a significant up-regulation (up to ninefold) of IL-1β, which is a critical indicator of inflammasome formation and activation. Of note, we could also observe that the induction of this pathway was independent of viral replication, as both UV-inactivated virus, and to a lesser extent heat-inactivated virus, all induced the secretion of IL-1β. As shown in Fig. 5 a, the modulation of inflammasome- and IL-1β–related genes also similarly occurred in the Lausanne cohort, where increased gene expression of caspase-1, IL-1RN, and the decrease in the expression of IL-1R2, further confirmed the activation of the inflammasome after YF17D vaccination. Altogether, these results confirm the importance of the inflammasome as a target of the YF17D vaccine. Whether this pathway is critical for the adjuvant effect of this vaccine remains to be determined, but is certainly suggested by the fact that the inflammasome is induced by immunization when alum is used as adjuvant (43). Moreover, IL-1β is known to play an important role in the regulation of T cell activation at multiple levels, and polymorphisms in the IL-1β gene have been linked to smallpox vaccine–induced fever (48).

We observed that YF17D stimulated the up-regulation of components of the complement cascade in blood cells, namely C1qA and C1qB. These molecules have been shown to induce maturation of DCs (49). Furthermore, distinct components of the complement pathway were found to be essential in the development of humoral and cellular immunity to another flavivirus, the West Nile Virus (50, 51). This may underline a possible role for the complement system in the establishment of immunity in response to YF17D vaccination.

The induction of a mixed Th1/Th2 profile by YF17D was suggested by Querèc et al., who reported that the vaccine triggers TLR2, 7, 8, and 9 on DCs (23); this was recently confirmed with in vivo data in humans (52). Our results corroborate these findings; we have demonstrated at the protein level that PBMCs isolated from YF17D–vaccinated volunteers display a mixed T helper cell phenotype. Cells from day
60 post-vaccination subjects, when stimulated ex vivo with YF17D-derived peptides, secreted Th1 and Th2 cytokines in their supernatants, as measured by CBA (Fig. 6 and Fig. S6 c). Peptide-stimulated PBMCs from day 28 expressed the Th1 cytokines IL-2 and/or IFN-γ, as revealed by intracellular cytokine staining (Fig. 7 a), and finally, PBMCs from day 365 after vaccination contained central memory T helper cells expressing surface markers typical of Th1 or Th2 cells when stimulated twice with immunostimulatory YF17D peptide pools (Fig. 7 b). Induction of the Th2 pathway by a vaccine is essential for the development of humoral immunity; in that context, we noted the induction of several B cell–specific genes in whole blood from volunteers vaccinated with YF17D, including POU2AF1, a transcription factor that is essential for mature B cell differentiation (53), and CD19, TNFRSF13B (BAFF) and TNFRSF17 (BCMA; Fig. 3 e), which are critical for B cell survival, persistence, and isotype switching (54). This late induction of B cell–associated genes (days 10 and 14) coincided with the onset of YF17D–specific neutralizing antibody production, which occurred by day 14 in the majority of the vaccinated volunteers (Table S2).

The MIMIC system confirmed that the YF17D vaccine can induce a mixed Th1/Th2 response, as measured by the secretion of the Th1 cytokines IL-2 and IFN-γ, and the Th2 cytokines IL-5 and -13 in the supernatants of the MIMIC co-cultures (Fig. 8 c), and by the production of IL-5 and -13 (Fig. 8 b) or IFN-γ (Fig. 8 a) by antigen–specific CD154+ T helper cells. The observation that both live and UV-inactivated YF17D virus stimulate an identical response clearly shows that viral replication is not required for the induction of adaptive immunity. Importantly, we show by gene array that most of the transcriptional nodes involved in the response to YF17D in vivo that were identified with the Montreal cohort (Fig. 2) are also induced in the Lausanne cohort, as well as in the in vitro MIMIC system (Table S3), leading to the mobilization of several of their downstream transcriptional targets. Specifically, we found that immunization with YF17D elicits the induction of IRF1, IRF7, IRF8, STAT1, and FOXO3a in all three datasets, all of which are master-switch genes required for the coordination of an efficient and protective immune response. Moreover, ICA followed by gene set enrichment (Table S4, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1) has revealed a significant enrichment of genes induced by IFNs and viruses among the three datasets, namely those from Montreal, Lausanne, and VaxDesign’s MIMIC system.

Our results highlight the critical role of innate immunity in the elicitation of the multilineage and broad immune responses observed herein, and demonstrate the complexity of the innate immune response that is generated upon vaccination with YF17D. Indeed, several effector molecules of the innate immune response, including complement, IFNs, the inflammasome, and several effector cells of innate immunity (i.e., macrophages, NK cells, and DCs, the latter being most likely the producers of type I IFNs [55]), are involved in this early response (day 3 and 7). Control of viral replication (Table S5, available at http://www.jem.org/cgi/content/full/jem.20082292/DC1) happens as this innate response precedes the emergence of YF17D–specific humoral and cellular immune responses. Interestingly, complement, IFNs, and the inflammasome can all impact on the quality of the adaptive immune response and trigger Th1/Th2 mixed immune responses (42). Notably, YF17D triggers TLR2, which is upstream of the Th2 pathway (56) and TLR7, 8, and 9, which trigger mostly the Th1 pathway (57). Our studies have also revealed that the mixed Th1/Th2 CD4+ response preceded B cell responses, as monitored by the detection of antibodies in serum of vaccinated subjects and the identification of gene expression signatures specific to B cell responses (Table S2 and Fig. 3 e). An important outcome of the early development of Th2 memory CD4+ T cells is the generation and persistence of a strong antibody response. As for CD8+ responses, they could certainly be involved in providing long-lasting protection against reexposure to the virus. In that context, it will be important to compare the immune response described herein to that of individuals that have been reexposed to the virus, such as those who live in endemic areas or who get reimmunized with the vaccine.

The results described herein identify unique features of protective immune responses which can now be used as benchmarks to design and monitor the development of novel vaccines. They demonstrate the complexity of this immune response and they highlight the fact that it is the sum of all arms of the immune response that is most probably required for the long-lasting protection induced by this vaccine; and they highlight the fact that it is this integrated immune response that constitutes the correlates of protection. In that context, systems biology becomes an essential tool to identify correlates of immune-mediated protection. The recent failure of the STEP HIV vaccine trial paves the way for the use of new immune monitoring strategies focused on the identification of multilineage and polyfunctional features of candidate vaccine–induced immune response.

MATERIALS AND METHODS
Vaccination of human volunteers and blood collection. The volunteer recruitment and vaccination protocols for this study were approved by the research ethics committee of the Centre Hospitalier de l’Université de Montréal (Montreal cohort; 20 volunteers), the Faculty of Biology and Medicine of the University of Lausanne (Lausanne cohort; 13 volunteers), and Emory University (Emory Cohort; 10 volunteers). Each recruited subject received a single 0.5-ml subcutaneous injection of the Sanofi-Pasteur 17D-204 live-attenuated YF virus vaccine YF-VAX (Montreal and Emory cohorts) or Stamaril (Lausanne cohort). For the Montreal cohort, 50 ml of blood were drawn from each volunteer in sodium-heparinized Vacutainer tubes (BD) on the day of vaccination (day 0) and 3, 7, 10, 14, 28, 60, 90, 180, and 365 d thereafter. PBMCs were isolated from these samples using standard Ficoll-Paque Plus (GE Healthcare) density gradient centrifugation and cryopreserved in bovine serum + 10% DMSO in liquid nitrogen. At each time point, an additional 10 ml of blood was collected from each volunteer in PaxGene tubes (QIAGEN), for whole-blood RNA isolation. Each collected subject received a single 0.5-ml subcutaneous injection of the Sanofi-Pasteur 17D-204 live-attenuated YF virus vaccine YF-VAX (Montreal and Emory cohorts) or Stamaril (Lausanne cohort). For the Montreal cohort, 50 ml of blood were drawn from each volunteer in sodium-heparinized Vacutainer tubes (BD) on the day of vaccination (day 0) and 3, 7, 10, 14, 28, 60, 90, 180, and 365 d thereafter. PBMCs were isolated from these samples using standard Ficoll-Paque Plus (GE Healthcare) density gradient centrifugation and cryopreserved in bovine serum + 10% DMSO in liquid nitrogen. At each time point, an additional 10 ml of blood was collected from each volunteer in PaxGene tubes (QIAGEN), for whole-blood RNA isolation. For the Lausanne cohort, whole blood was collected in PaxGene tubes at days 0, 3, and 7 after vaccination. YF17D–specific seroconversion and viremia were determined as described in Tables S2 and S5, respectively.
Gene array analysis of whole-blood and VaxDesign samples. Whole-blood total RNA was purified from PazGene tubes using RNA extraction kits (QIAGEN). Quantification was performed using a spectrophotometer (NanoDrop Technologies) and RNA quality was assessed using the Experion automated electrophoresis system (Bio-Rad Laboratories). Total RNA was then amplified and labeled using the Illumina TotalPrep RNA Amplification kit, which is based on the Eberwine amplification protocol (58). This protocol involves a first cDNA synthesis step followed by in vitro transcription for cRNA synthesis. The biotinylated cRNA was hybridized onto Illumina Human RefSeq-8 BeadChips v2 (Montreal and Lausanne samples) or v3 (VaxDesign samples) at 58°C for 20 h and quantified using Illumina BeadStation 500GX scanner and Illumina BeadStuto v3 software.

Illumina probe data were exported from BeadStudio as raw data and screened for quality. Samples failing chip visual inspection and control examination were removed. Gene expression data were analyzed using Bioconductor (59), an open-source software library for the analyses of genomic database on R, which is a language and environment for statistical computing and graphics (www.r-project.org). The R software package was used to first filter out probes with intensities below background in all samples, and then to minimum replace (a surrogate replacement policy) values below background using the mean background value of the built-in Illumina probe controls as an alternative to background subtraction (which may introduce negative values) to reduce “overinflated” expression ratios determined in subsequent steps, and finally quantile normalize the probe intensities. The resulting matrix showing probes as rows and samples as columns was log-transformed and used as input for linear modeling using BioConductor linear models for microarray analysis (LIMMA) [60]. The LIMMA package (61) was used to identify differentially expressed genes (pDFR < 0.05; fold change greater than −1.3 or >1.3) at days 3, 7, 10, 14, 28, and 60, compared with day 0 for the Montreal samples, at days 3 and 7 compared with day 0 for the Lausanne samples, and at days 3 and 7 compared with the respective control for the VaxDesign samples. Our microarray data are available through the National Center for Biotechnology Information Gene Expression Omnibus (GEO) under series accession no. GSE13699.

qPCR validation. Changes in gene expression observed by microarray analyses were verified by qPCR. The expression of 43 genes, which were chosen according to our microarray results and to biomedical literature, was analyzed on samples obtained at day 0 and 7 after vaccination from the Montreal and Lausanne cohorts. To further validate our microarray data, we also performed qPCR analysis on RNA samples (day 0 and 7) from 10 YF17D-vaccinated volunteers enrolled in another vaccination trial conducted by the Emory Vaccine Center in Atlanta, GA (a gift from B. Pulendran). qPCR analysis was performed at the genomics platform of the Institute for Research in Immunology and Cancer (Montreal), as previously described (62).

Identification of transcription factors and curated gene sets. Transcription factors were identified using ICA and gene set enrichment as described in Teschendorff et al. (63). ICA was performed on the expression profiles of the whole-blood and ex vivo model gene arrays (Montreal, Lausanne, and VaxDesign) on each day individually, as well as on the whole datasets from each study. The CRAN package fastICA (v1.1-9) was used to carry out the ICA. Genes in each component were chosen for enrichment by selecting genes with loads below the 0.2 fifth percentile or above the 97.5th percentile. Gene set enrichment was done on the C2 “curated gene sets” and C3 “motif gene sets” collections of MsigDB. The resulting P values were Benjamini-Hochberg adjusted to keep the false discovery rates within each component <5%. Results annotated with unknown transcription factors that were discerned. Additionally, at least one gene in the gene sets used for enrichment had to be differentially expressed (see Gene array analysis of whole blood and VaxDesign samples) on at least one of the available time points up to day 14.

In vitro infection of immature DCs with YF17D. Stocks of live YF17D virus were prepared in our laboratory by infecting Vero cell monolayers grown in DME medium (Sigma-Aldrich) supplemented with 10% X-Vivo 15 medium (Lonza), with YF17D, and harvesting the culture supernatants when severe histopathology could be observed (6–7 d). The virus particles were concentrated using Centrifuge Plus-20 columns (100 kD cutoff, Millipore). Viral stocks were titrated on Vero cells by lysis plaque assay. The virus was either heat-inactivated by incubation at 65°C for 1 h, or UV-inactivated at a dose of 0.72 J/cm² in a Stratalinker 1800 (Stratagene). Inactivated YF17D was tested by plaque assay to ensure total inactivation.

Immature DCs were generated by culturing monocytes for 6 d in the presence of 100 ng/ml GM-CSF (R&D Systems) and 25 ng/ml IL-4 (R&D Systems). The cells were then incubated with live, UV-inactivated or heat-inactivated YF17D, at a multiplicity of infection of 10. After 24 and 48 h, supernatants were collected and analyzed using an IL-1β ELISA kit (BD).

Proliferation and cytokine secretion assays. PBMCs from vaccinated volunteers were labeled with CFSE (Invitrogen), as previously described (64). 2 million cells were incubated in polypropylene snap-cap tubes (Falcon) in the presence of YF17D-derived peptide pools (Fig. S6 a) at a final concentration of 2 μg/ml/peptide, SEB (50 ng/ml, Toxin Technology) or nothing (nonstimulated; NS). After 24 h of incubation at 37°C/5% CO2, 120 μl of supernatant was withdrawn from each tube and frozen at −80°C for subsequent cytokine analysis. The same volume of fresh medium was replaced in each tube, and 5 d later (6 d total incubation), the cells were harvested and stained with anti-CD3, -CD4, and -CD8 antibodies (BD). The cells were collected on a BD LSRII flow cytometer and the results were analyzed using the BD FACS Diva software. The BD Th1/Th2 CBA array (BD) was used to measure levels of IL-2, IL-4, IL-5, IL-10, IFN-γ, and TNF in PBMCs supernatants, as suggested by the manufacturer.

Flow cytometric analysis of IFN-γ/IL-2–producing activated CD4+ T cells. To assess the cytokine production ability of YF17D-specific helper T cells, 2 million PBMCs from vaccinated subjects (day 14 and 28) were stimulated for 6 h with YF17D-derived peptide pools, in the presence of Brefeldin A (Sigma-Aldrich), and then stained with anti-CD3 and -CD4 antibodies. They were then permeabilized and stained with anti-CD154, IL-2, and IFN-γ (BD). To determine the T helper phenotype of long-term, vaccine-specific CD4+ T cells, 2 million PBMCs were stimulated for 6 d with YF17D peptide pools, and subsequently restimulated with the same pools for 12 h, in the presence of Brefeldin A. Non-stimulated cells were used as controls. The cells were then stained with anti-CD3, -CD4, -CD8, -CD45RA, -CCR7, -CCR4, -CXCR3, and -CCR6 antibodies (BD). After permeabilization, they were stained for intracellular CD154 and fixed.

The MIMIC co-culture system. PBMCs used in the assays were acquired from normal healthy donors enrolled in a VaxDesign Corporation apheresis study program (protocol CRRI 0906009). Blood collections were performed at Florida’s Blood Centers (Orlando, FL) using standard techniques. The enriched leukocytes were isolated and cryopreserved. Human DCs were prepared as described above. After 5 d of culture with IL-4 and GM-CSF, the DCs were infected with a 1:100 dilution of the live-attenuated YF-VAX vaccine. After 24 h, 5% human AB serum was added to the media to quench the infection. Alternatively, some of the DCs were pulsed with a 1:100 dilution of YF-VAX (YF) that had been UV-inactivated. On the sixth day, all DCs were matured with an overnight treatment of 25 ng/ml TNF-α (R&D Systems).

CD4+ T cell stimulation assay. Frozen stocks of autologous PBMCs were used as a source of lymphocytes. Purified CD4+ T cells were co-cultured with uninfected or YF17D-pulsed DCs at a ratio of 60:1 for 14 d; thereafter, the activated lymphocytes were harvested and evaluated for effector activity using autologous DCs as APCs. The T cells and APCs were co-cultured for 7 h, stained with CD4 antibody, permeabilized, and labeled intracellularly with anti-IFN-γ, –IL-5, –IL-13, and -CD154 antibodies.

Multiplex cytokine analysis. At the time the lymphocytes were harvested from DC/T cell co-cultures, the supernatants were also collected and stored
frozen until analyzed for cytokine production using the Beadlyte human 22-plex Multi-cytokine Detection System (Millipore) on a Bio-Plex reader (Bio-Rad Laboratories).

**Online supplemental materials.** Fig. S1 shows the transcriptional network of differentially expressed genes after YF17D vaccination, as inferred by gene set enrichment. Fig. S2 shows the correlation of gene expression between Illumina array and qPCR data (Montreal cohort). Fig. S3 shows a heat map of fold change gene expression (all 43 genes tested) between day 0 and day 3 or 7 after YF17D vaccination, as measured by qPCR. Fig. S4 shows the production of IL-1β by DCs in response to YF17D. Fig. S5 shows the expression of Ki67 by different subsets of PBMCs after YF17D vaccination. Fig. S6 shows the induction of antigen-specific CD4⁺ and CD8⁺ T cell responses by YF17D vaccination. Fig. S7 shows the gating strategy used to identify central memory Th1 and Th2 cells by flow cytometry. Table S1 shows the results of qPCR analysis of RNA samples from three independent YF17D vaccination studies. Table S2 shows the neutralizing humoral immune response elicited by the YF17D vaccine in the Montreal cohort. Table S3 shows a comparison between the transcription factors induced by YF17D in the Montreal cohort, the Lausanne cohort, and VaxDesign’s MIMIC system. Table S4 shows the induction by YF17D of Common gene sets in the Montreal, Lausanne, and VaxDesign microarray data. Table S5 shows the development of viremia after vaccination with YF17D. Document S1 shows the list of significant genes modulated after YF17D vaccination. Document S2 shows the lists of genes selected to make up the different gene sets used for Figs. 3 and 5 a. These lists were derived from published literature. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20082292/DC1.

We thank M. Lainesse and R. Bordi for expert technical assistance. YF-VAX was generously provided by Sanofi Pasteur. We thank Dr. Bali Pulendran for giving us YF-VAX and Dr. J. L’Age-Stehr for protocol discussion and support in the recruitment of volunteers from Lausanne.

This study was supported by funds from Genome Canada, Genome Quebec, the Canadian Network for Vaccines and Immunotherapeutics (CANVAC), the Institut National de la Santé et de la Recherche Médicale (INSERM), and the IAVI Innovation Fund. R.P. Sekaly is the Canada Research Chair in Human Immunology. D. Gaucher is the recipient of a postdoctoral fellowship from the “Fonds de la recherche en santé du Québec” R. Thérien is supported by a scholarship from INSERM.

The authors have no conflicting financial interest.

Submitted: 14 October 2008
Accepted: 20 November 2008

**REFERENCES**


Figure S1. Transcriptional network of differentially expressed genes after YF17D vaccination, as inferred by gene set enrichment. Network representation of inferred transcription factors [Xie, X., J. Lu, E.J. Kulbokas, T.R. Golub, V. Mootha, K. Lindblad-Toh, E.S. Lander, and M. Kellis. 2005. Nature, 434:338–345] and predicted target genes that are significantly modulated. Node colors indicate fold change of gene expression between day 0 and 7, in \( n = 11 \) volunteers. Rectangular nodes indicate transcription factors identified by gene enrichment; the different shapes indicate genes in the different functional categories of Fig. 3 (a–e). Genes in gray boxes are grouped to enhance readability. Genes that were subsequently evaluated by RT-PCR are identified by an asterisk.
Figure S2. Correlation of gene expression, at day7/day0, showing fold change between Illumina array and qPCR data (Montreal cohort), using the common genes between the Illumina probe set and the qPCR gene list. $r$ represents the Spearman correlation coefficient.
Figure S3. Heat map of fold change gene expression (all 43 genes tested) between day 0 and day 3 or 7 after YF17D vaccination as measured by qPCR. All fold changes reported for the Montreal and the Emory data are between day 0 and 7; for the Lausanne data, the sample labels indicate D3 or D7 for day 3 or 7, respectively.

Figure S4. YF17D virus induces IL-1β production by DCs. Monocyte-derived DCs were generated and incubated with live (YF), UV-inactivated (UV), or heat-inactivated (HI) YF17D. NI, noninfected cells. After 24 or 48 h, the supernatants were harvested and the levels of IL-1β secreted by the cells were determined by ELISA. In both experiments, there is no 24 h sample for DCs incubated with UV-attenuated virus. This depicts the results from two representatives out of three separate experiments. The results for the third experiment are shown in Fig. 5b.
Figure S5. Analysis of Ki67 expression in different subsets of PBMCs. (a) Gating strategy to identify lymphocytes, CD4+ T cells, CD8+ T cells, NK cells (CD3−CD4−CD8−), and non-T cells (CD3−CD4−CD8−) by flow cytometry. (b–f) PBMCs sampled at day 0, 3, 7, 10, 14, and 28 after vaccination from 6 volunteers were stained with anti-Ki67 and other specific antibodies to identify the distinct cell subsets described in a. Significant percentages of Ki67-positive cells in each subset were then analyzed by a paired Student’s t test. Data for the most significant time points are presented. Each point represents individual volunteer. *, P < 0.05; **, P < 0.01.
Figure S6. YF17D vaccination induces antigen-specific CD4+ and CD8+ T cell responses. (a) Schematic representation of the 22 YF17D-derived peptide pools used in this study. A total of 851 overlapping (by 11 amino acids) peptides, spanning the entire YF17D proteome, were obtained from the Emery Vaccine Center, Atlanta. These 15-mer peptides were grouped in 22 pools (containing 28–46 peptides each), according to the YF17D protein they were derived from. PBMCs from 18 volunteers from day 60 after vaccination were labeled with CFSE and stimulated for 6 d with the YF17D-derived peptide pools, and then analyzed by FACS for their proliferative response. The gating strategy is described in b. (c and d) The heat maps represent the percentage of cell proliferation over background for CD4+ T cells and CD8+ T cells, respectively. Positive pools were defined as pools stimulating ≥0.2% proliferation over nonstimulated values. (e) At 24 h of culture, supernatants were analyzed by CBA to determine the Th1/Th2 cytokine secretion profile of PBMCs from each volunteer, in response to each peptide pool. The heat maps represent the data for the same six volunteers. The Th1/Th2 profiles determined this way for all the volunteers and pools are shown in e.
Figure S7. Gating strategy used to identify central memory Th1 and Th2 cells by flow cytometry. PBMCs from vaccinated volunteers (day 365 after vaccination) were stimulated and restimulated with immunostimulatory YF17D-derived peptide pools. Cells were harvested and stained for flow cytometry with antibodies against CD3, CD4, CD8, CCR7, CD45RA, CD154, CXCR3, CCR4, and CCR6. CD3+CD4+ cells (T helper cells) that do not express CD45RA but are positive for CCR7 (central memory T helper cells) were first identified. Of those, the antigen-specific cells (CD154+) were gated on, and Th1 cells were identified as being CXCR3+ CCR4–. Th2 cells were identified as CXCR3– CCR4+ CCR6–.
Supplemental Document 1: YF17D vaccination regulates the transcription of numerous genes in total blood cells. Volunteers were vaccinated with YF17D and their total blood was collected at Days 0, 3, 7, 10, 14, 28, and 60 post-vaccination. Total RNA was isolated from the blood samples, amplified and hybridized to Illumina Human RefSeq v2. Samples from 11-15 volunteers per time point were used for analysis. The list enumerates all the modulated genes with a fold change value < -1.3 or > 1.3 (time point compared to Day 0), with or without a p value < 0.05.

<table>
<thead>
<tr>
<th>ProbeID</th>
<th>Symbol</th>
<th>NCBI gene symbol</th>
<th>P-value</th>
<th>Fold change</th>
<th>Description</th>
<th>Ontology</th>
</tr>
</thead>
<tbody>
<tr>
<td>2120341</td>
<td>TLR7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6840750</td>
<td>AXUD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2640576</td>
<td>SAMD4A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3310243</td>
<td>TOR1B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6220692</td>
<td>IFITM1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1010064</td>
<td>PARP14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4210008</td>
<td>IFIH1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6480730</td>
<td>LGP2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5220477</td>
<td>IFI27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3610601</td>
<td>CDKN1C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980491</td>
<td>SCARB2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1190452</td>
<td>FBXO6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6960022</td>
<td>PTGDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1580673</td>
<td>GALM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1240253</td>
<td>NCOA7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6220450</td>
<td>DHRS9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5720743</td>
<td>PARP10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4280725</td>
<td>HES4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1850538</td>
<td>LGALS3BP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7150521</td>
<td>CENTA2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7200682</td>
<td>TDRD7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6270382</td>
<td>NTNG2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4180546</td>
<td>TIMM10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>630450</td>
<td>IFIT2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>430021</td>
<td>IFIT3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>770364</td>
<td>RTP4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60482</td>
<td>IFI16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1070423</td>
<td>APOBEC3A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>407001</td>
<td>LGALS3BP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980491</td>
<td>SCARB2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1190452</td>
<td>FBXO6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1240253</td>
<td>NCOA7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6220450</td>
<td>DHRS9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5720743</td>
<td>PARP10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4280725</td>
<td>HES4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1850538</td>
<td>LGALS3BP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7150521</td>
<td>CENTA2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7200682</td>
<td>TDRD7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6270382</td>
<td>NTNG2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4180546</td>
<td>TIMM10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>630450</td>
<td>IFIT2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>430021</td>
<td>IFIT3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>770364</td>
<td>RTP4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60482</td>
<td>IFI16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
<td>Log2 Fold Change</td>
<td>p-Value</td>
<td>q-Value</td>
<td>Description</td>
<td>Log2 Fold Change</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>---------</td>
<td>---------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>KIAA0319L</td>
<td>Homophilic cell adhesion</td>
<td>0.0367</td>
<td>0.0013</td>
<td>0.56775</td>
<td>Homophilic cell adhesion</td>
<td>0.0013</td>
</tr>
<tr>
<td>GADD45B</td>
<td>Growth arrest and DNA-damage-inducible, beta apoptosis</td>
<td>0.62079</td>
<td>0.3606</td>
<td>0.58372</td>
<td>Growth arrest and DNA-damage-inducible, beta apoptosis</td>
<td>0.62079</td>
</tr>
<tr>
<td>TMEM51</td>
<td>Transmembrane protein 51 integral to membrane</td>
<td>0.78278</td>
<td>0.6055</td>
<td>0.14705</td>
<td>Transmembrane protein 51 integral to membrane</td>
<td>0.78278</td>
</tr>
<tr>
<td>RHBDF2</td>
<td>Rhomboid 5 homolog 2</td>
<td>0.91613</td>
<td>0.2446</td>
<td>0.05085</td>
<td>Rhomboid 5 homolog 2</td>
<td>0.91613</td>
</tr>
<tr>
<td>ANKFY1</td>
<td>Ankyrin repeat and FYVE domain containing 1 endocytosis, metal ion binding</td>
<td>0.73191</td>
<td>0.7832</td>
<td>0.15602</td>
<td>Ankyrin repeat and FYVE domain containing 1 endocytosis, metal ion binding</td>
<td>0.73191</td>
</tr>
<tr>
<td>C1orf85</td>
<td>Chromosome 1 open reading frame 85</td>
<td>0.16603</td>
<td>0.3056</td>
<td>0.27883</td>
<td>Chromosome 1 open reading frame 85</td>
<td>0.16603</td>
</tr>
<tr>
<td>TAGLN</td>
<td>Transgelin muscle development</td>
<td>0.77311</td>
<td>0.0851</td>
<td>0.05219</td>
<td>Transgelin muscle development</td>
<td>0.77311</td>
</tr>
<tr>
<td>SNTB1</td>
<td>SNTB1, zona pellucida domain protein 1</td>
<td>0.67533</td>
<td>0.3314</td>
<td>0.02535</td>
<td>SNTB1, zona pellucida domain protein 1</td>
<td>0.67533</td>
</tr>
<tr>
<td>UBA7</td>
<td>Ubiquitin-activating enzyme E1-like ubiquitin cycle</td>
<td>0.65191</td>
<td>0.2847</td>
<td>0.43993</td>
<td>Ubiquitin-activating enzyme E1-like ubiquitin cycle</td>
<td>0.65191</td>
</tr>
<tr>
<td>CD74</td>
<td>CD74 antigen cell proliferation, T cell selection, negative regulation of apoptosis</td>
<td>0.2818</td>
<td>0.1461</td>
<td>0.0165</td>
<td>CD74 antigen cell proliferation, T cell selection, negative regulation of apoptosis</td>
<td>0.2818</td>
</tr>
<tr>
<td>ATF5</td>
<td>Activating transcription factor 5 regulation of cell cycle</td>
<td>0.96546</td>
<td>0.9594</td>
<td>0.5762</td>
<td>Activating transcription factor 5 regulation of cell cycle</td>
<td>0.96546</td>
</tr>
<tr>
<td>ATF3</td>
<td>Activating transcription factor 3 regulation of transcription</td>
<td>1</td>
<td>0.8223</td>
<td>0.18728</td>
<td>Activating transcription factor 3 regulation of transcription</td>
<td>1</td>
</tr>
<tr>
<td>IRF9</td>
<td>Interferon-stimulated transcription factor 3, gamma 48kDa response to virus</td>
<td>0.86965</td>
<td>0.0381</td>
<td>0.05766</td>
<td>Interferon-stimulated transcription factor 3, gamma 48kDa response to virus</td>
<td>0.86965</td>
</tr>
<tr>
<td>DKFZp761E198 protein</td>
<td>Apolipoprotein B mRNA editing catalytic polypeptide-like 3F</td>
<td>0.32653</td>
<td>0.026</td>
<td>0.29708</td>
<td>Apolipoprotein B mRNA editing catalytic polypeptide-like 3F</td>
<td>0.32653</td>
</tr>
<tr>
<td>Gene Symbol</td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIGLEC5</td>
<td>Sialic acid binding Ig-like lectin 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYADM</td>
<td>Membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5orf4</td>
<td>Serpin peptidase inhibitor, clade A (alpha-1 antitrypsin), member 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSDA</td>
<td>Protein amino acid glycosylation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNFRSF13B</td>
<td>Tumor necrosis factor receptor superfamily, member 13B cell surface receptor linked signal transduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MS4A3</td>
<td>Tumor necrosis factor receptor superfamily, member 17 immune response</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARMET</td>
<td>Sialic acid binding Ig-like lectin 10 cell adhesion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLJ20699</td>
<td>Phosphatase and actin regulator 2 actin binding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPB49</td>
<td>Thioredoxin domain containing 13 electron transport</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLC1SA</td>
<td>Aldehyde dehydrogenase 3 family, member B1 metabolism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUSAP1</td>
<td>Adiponectin receptor 1 hormone-mediated signaling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C22orf13</td>
<td>Chromosome 22 open reading frame 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROPN1B</td>
<td>Ropporin, rhophilin associated protein 1B sperm motility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TXNDC13</td>
<td>Chromosome 19 open reading frame 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDH3B1</td>
<td>DnaJ protein folding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2RY13</td>
<td>Purinergic receptor P2Y, G-protein coupled, 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLC2A6</td>
<td>Solute carrier family 2 (facilitated glucose transporter), member 6 carbohydrate transport</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CENPM</td>
<td>Chromosome 22 open reading frame 18 nucleus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNRPG</td>
<td>Small nuclear ribonucleoprotein polypeptide G RNA splicing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MKRN1</td>
<td>Makorin, ring finger protein, 1 protein ubiquitination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCNB2</td>
<td>Cyclin B2 regulation of cell cycle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CECR6</td>
<td>Cat eye syndrome chromosome region, candidate 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MED25</td>
<td>Mediator of RNA polymerase II transcription, subunit 25 homolog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRDX4</td>
<td>Peroxiredoxin 4 I-kappaB phosphorylation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACOT7</td>
<td>Acyl-CoA thioesterase 7 lipid metabolism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYL6B</td>
<td>Myosin light chain 1 slow muscle development</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPS10</td>
<td>Ribosomal protein S10 structural constituent of ribosome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TBL1X</td>
<td>Transducin (beta)-like 1X-linked regulation of transcription</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5orf4</td>
<td>Chromosome 5 open reading frame 4 metabolism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-A</td>
<td>Major histocompatibility complex, class I, A antigen presentation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NME1</td>
<td>Non-metastatic cells 1, protein regulation of apoptosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XBP1</td>
<td>X-box binding protein 1 immune response, regulation of transcription</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensembl ID</td>
<td>Full Name</td>
<td>Description</td>
<td>p-value</td>
<td>q-value</td>
<td>Log2 Fold Change</td>
<td>BLAST E-value</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
<td>-------------</td>
<td>---------</td>
<td>---------</td>
<td>-----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>1690484</td>
<td>CMPK</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5550424</td>
<td>CDC2L6</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5550040</td>
<td>FIS1</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5360102</td>
<td>C20orf108</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1580538</td>
<td>GYPC</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3800243</td>
<td>PBEF1</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1090400</td>
<td>RPL7A</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5720605</td>
<td>SNURF</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7550519</td>
<td>FLJ11151</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7560446</td>
<td>ZNF217</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4540414</td>
<td>RPS18</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3190193</td>
<td>RPL30</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6980082</td>
<td>RPL22</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1450246</td>
<td>PCBP2</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>630364</td>
<td>PANX2</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>160167</td>
<td>FAU</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>430324</td>
<td>PTOV1</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70390</td>
<td>HDC</td>
<td>unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3E-05</td>
<td>HSD17B11</td>
<td>dehydrogenase/reductase (SDR family) member 8 steroid biosynthesis</td>
<td>0.1047</td>
<td>0.02127</td>
<td>-1.18</td>
<td>0.45597</td>
</tr>
<tr>
<td>3.3E-05</td>
<td>TBC1D14</td>
<td>GTPase activator activity</td>
<td>0.94519</td>
<td>0.6898</td>
<td>-1.23</td>
<td>1.03</td>
</tr>
<tr>
<td>2E-05</td>
<td>TOPORS</td>
<td>topoisomerase I binding, arginine/serine-rich protein ubiquitination</td>
<td>0.11382</td>
<td>0.58942</td>
<td>-1.39</td>
<td>0.27</td>
</tr>
<tr>
<td>0.8333</td>
<td>FCER1A</td>
<td>Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide immune response, Ig E binding</td>
<td>0.2786</td>
<td>0.19992</td>
<td>-1.03</td>
<td>0.23</td>
</tr>
<tr>
<td>0.0307</td>
<td>OSBPL8</td>
<td>oxysterol binding protein-like 8 steroid metabolism</td>
<td>0.053</td>
<td>0.55497</td>
<td>-1.28</td>
<td>0.11</td>
</tr>
<tr>
<td>0.1003</td>
<td>GNG10</td>
<td>guanine nucleotide binding protein (G protein), gamma 10 G-protein coupled receptor protein signaling pathway</td>
<td>0.17569</td>
<td>0.7384</td>
<td>-1.32</td>
<td>0.27</td>
</tr>
<tr>
<td>0.0016</td>
<td>FOXO1</td>
<td>forkhead box O1 anti-apoptosis, transcription</td>
<td>0.16797</td>
<td>0.0956</td>
<td>-1.23</td>
<td>0.45</td>
</tr>
<tr>
<td>0.0147</td>
<td>ABHD5</td>
<td>abhydrolase domain containing 5 proteolysis and peptidolysis</td>
<td>0.37938</td>
<td>0.494</td>
<td>-1.29</td>
<td>0.99</td>
</tr>
<tr>
<td>0.0075</td>
<td>SORL1</td>
<td>sortilin-related receptor, L steroid metabolism</td>
<td>0.45452</td>
<td>0.8202</td>
<td>-1.32</td>
<td>0.61</td>
</tr>
<tr>
<td>0.001</td>
<td>KLRB1</td>
<td>killer cell lectin-like receptor subfamily B, member 1 cell surface receptor linked signal transduction</td>
<td>0.32475</td>
<td>0.4173</td>
<td>-1.38</td>
<td>0.72</td>
</tr>
<tr>
<td>0.2212</td>
<td>USP10</td>
<td>ubiquitin specific peptidase 10 ubiquitin cycle</td>
<td>0.26279</td>
<td>0.5275</td>
<td>-1.15</td>
<td>0.53</td>
</tr>
<tr>
<td>0.0521</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.4749</td>
<td>RNF11</td>
<td>ring finger protein 11 protein ubiquitination during ubiquitin-dependent protein catabolism</td>
<td>0.84345</td>
<td>0.8326</td>
<td>1.08</td>
<td>0.83</td>
</tr>
<tr>
<td>0.616</td>
<td>LST1</td>
<td>leukocyte specific transcript 1 negative regulation of lymphocyte proliferation</td>
<td>0.23233</td>
<td>0.7411</td>
<td>-1.07</td>
<td>0.76</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.0521</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>0.001</td>
<td>RPL7A</td>
<td>ribosomal protein L7a ribosome biogenesis and assembly</td>
<td>0.39059</td>
<td>0.0556</td>
<td>-1.18</td>
<td>0.25</td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
<td>Change</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOC349114</td>
<td>Hypothetical protein LOC349114</td>
<td>-1.26</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-DRB5</td>
<td>Major histocompatibility complex, class II, DR beta 5 antigen processing</td>
<td>-1.19</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGLYRP1</td>
<td>Peptidoglycan recognition protein 1 innate immune response</td>
<td>-1.23</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAM101B</td>
<td>Family with sequence similarity 101, member B</td>
<td>-1.39</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FCGR3A</td>
<td>Fc fragment of IgG, low affinity IIIa, receptor immune response</td>
<td>-1.22</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPS27L</td>
<td>Ribosomal protein S27-like structural constituent of ribosome</td>
<td>-1.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRIM58</td>
<td>Tripartite motif-containing 58</td>
<td>-1.36</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF3R</td>
<td>Colony stimulating factor 3 receptor (granulocyte) defense response</td>
<td>-1.06</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PFDN5</td>
<td>Prefoldin 5 regulation of transcription</td>
<td>-1.17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPS4X</td>
<td>Ribosomal protein S4, X-linked structural constituent of ribosome</td>
<td>-1.35</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPL27</td>
<td>Ribosomal protein L27 structural constituent of ribosome</td>
<td>-1.39</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNCA</td>
<td>Synuclein, alpha (non A4 component of amyloid precursor) anti-apoptosis</td>
<td>-1.61</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VNN1</td>
<td>Vanin 1 nitrogen compound metabolism, cell motility</td>
<td>-1.23</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VNN2</td>
<td>Vanin 2 nitrogen compound metabolism, cell motility</td>
<td>-1.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCR</td>
<td>Breakpoint cluster region intracellular signaling cascade</td>
<td>-1.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## TLR-Associated and IFN-Induced Genes

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C3AR1</td>
<td>Complement C3a receptor 1</td>
<td>Complement component 3a receptor, expressed in B cells and plasma cells.</td>
</tr>
<tr>
<td>RIPK1</td>
<td>Receptor-interacting protein kinase 1</td>
<td>Important in apoptosis and cell survival.</td>
</tr>
<tr>
<td>SP110</td>
<td>Serpin peptidase inhibitor, clade G (C1)</td>
<td>Involved in the regulation of complement activation.</td>
</tr>
<tr>
<td>TBK1</td>
<td>TANK-binding kinase 1</td>
<td>Plays a role in interferon signaling.</td>
</tr>
<tr>
<td>AIM2</td>
<td>Absent in melanoma 2</td>
<td>Involved in the recognition of nucleic acids.</td>
</tr>
<tr>
<td>C1QB</td>
<td>Complement factor C1q subcomponent B</td>
<td>Complement component, involved in the classical pathway.</td>
</tr>
<tr>
<td>TLR3</td>
<td>Toll-like receptor 3</td>
<td>Recognizes conserved motifs in bacterial and viral pathogens.</td>
</tr>
<tr>
<td>IFIT3</td>
<td>Interferon-induced protein with antiviral activity 3</td>
<td>Acts as an antiviral effector.</td>
</tr>
<tr>
<td>SPP1</td>
<td>Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)</td>
<td>Involved in bone metabolism and immune cell activation.</td>
</tr>
<tr>
<td>IFI30</td>
<td>Interferon-induced protein with antiviral activity 30</td>
<td>Acts as an antiviral effector.</td>
</tr>
<tr>
<td>G1P2</td>
<td>Glycoprotein 2 (manose-6-phosphate receptor)</td>
<td>Involved in the recycling of mannose-6-phosphate receptors.</td>
</tr>
<tr>
<td>MX1</td>
<td>Myxovirus resistance 1</td>
<td>Acts as an antiviral effector.</td>
</tr>
<tr>
<td>IRF7</td>
<td>Interferon regulatory factor 7</td>
<td>Involved in the regulation of interferon responses.</td>
</tr>
<tr>
<td>IRF3</td>
<td>Interferon regulatory factor 3</td>
<td>Involved in the regulation of interferon responses.</td>
</tr>
<tr>
<td>IL15</td>
<td>Interleukin-15</td>
<td>Involved in the regulation of immune responses.</td>
</tr>
</tbody>
</table>

## References

Inflammasome-associated genes

NK cell-associated genes

Dendritic cell-associated genes

B cell-associated genes

Inflammatory-associated genes

MACPOLL-1 associated genes

NK2 cell-associated genes

Immune-suppressing genes

Effectors

Macrophage-associated genes

EW1

Dendritic cell-associated genes

NK cell-associated genes

B cell-associated genes

Inflammatory-associated genes

Effectors

Macrophage-associated genes
Supplemental Table 1. qPCR analysis of RNA samples from three independent YF17D vaccination studies

<table>
<thead>
<tr>
<th>Gene</th>
<th>Montreal</th>
<th>Emory</th>
<th>Lausanne</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADORA2A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1Qa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1Qb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTL5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTS51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F2K2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E4F2K2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOMES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETS2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IKBKG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL1B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL1RN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF8</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

No change

<table>
<thead>
<tr>
<th>Gene</th>
<th>Montreal</th>
<th>Emory</th>
<th>Lausanne</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADORA2A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1Qa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1Qb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTL5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTS51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F2K2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E4F2K2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOMES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETS2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IKBKG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL1B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL1RN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF8</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Down

<table>
<thead>
<tr>
<th>Gene</th>
<th>Montreal</th>
<th>Emory</th>
<th>Lausanne</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADORA2A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1Qa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1Qb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTL5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTS51</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F2K2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E4F2K2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOMES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETS2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IKBKG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL1B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL1RN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF8</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total number of samples per study

<table>
<thead>
<tr>
<th>Locality</th>
<th>Montreal</th>
<th>Emory</th>
<th>Lausanne</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>13</td>
<td>13</td>
<td>13</td>
</tr>
</tbody>
</table>

RNA samples (day 0 and 7 after vaccination) from three independent YF17D vaccination studies (Montreal, Emory, and Lausanne) were analyzed by qPCR for the expression of 43 genes. Those genes were selected according to our microarray results and to biomedical literature. "Up" samples had a fold change (day 7 vs. day 0) of ≥1.3, whereas "down" samples had a fold change of less than or equal to −1.3.
Supplemental Table 2. The humoral immune response elicited by YF vaccination is variable

<table>
<thead>
<tr>
<th>Volunteer</th>
<th>0</th>
<th>3</th>
<th>7</th>
<th>10</th>
<th>14</th>
<th>28</th>
<th>60</th>
<th>90</th>
<th>180</th>
<th>360</th>
</tr>
</thead>
<tbody>
<tr>
<td>YF001</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/640</td>
<td>1/640</td>
</tr>
<tr>
<td>YF002</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/320</td>
<td>1/320</td>
<td>1/80</td>
<td>1/80</td>
</tr>
<tr>
<td>YF003</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
<td>1/160</td>
</tr>
<tr>
<td>YF004</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/320</td>
<td>1/320</td>
<td>1/160</td>
<td>1/160</td>
<td>1/640</td>
<td>1/640</td>
</tr>
<tr>
<td>YF005</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/160</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
<td>1/160</td>
<td>1/160</td>
</tr>
<tr>
<td>YF006</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/320</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
<td>1/80</td>
<td>1/80</td>
</tr>
<tr>
<td>YF007</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/80</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
<td>1/640</td>
<td>1/640</td>
</tr>
<tr>
<td>YF008</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/1280</td>
</tr>
<tr>
<td>YF009</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/1280</td>
<td>1/1280</td>
</tr>
<tr>
<td>YF010</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/2560</td>
<td>1/2560</td>
<td>N/D</td>
<td>N/D</td>
<td>N/D</td>
<td>N/D</td>
</tr>
<tr>
<td>YF011</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/320</td>
<td>1/320</td>
</tr>
<tr>
<td>YF012</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>320</td>
</tr>
<tr>
<td>YF013</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/160</td>
<td>1/160</td>
</tr>
<tr>
<td>YF014</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/1280</td>
<td>1/640</td>
<td>1/640</td>
</tr>
<tr>
<td>YF015</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
<td>1/160</td>
<td>1/160</td>
</tr>
<tr>
<td>YF016</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/160</td>
<td>1/160</td>
</tr>
<tr>
<td>YF017</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
<td>1/320</td>
</tr>
<tr>
<td>YF018</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/160</td>
<td>1/160</td>
</tr>
<tr>
<td>YF019</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
<td>1/160</td>
</tr>
<tr>
<td>YF020</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1/640</td>
<td>1/640</td>
<td>1/640</td>
<td>1/320</td>
<td>1/320</td>
<td>1/320</td>
</tr>
</tbody>
</table>

YF17D-specific seroconversion by each volunteer after vaccination was assessed by measuring the titer of neutralizing antibodies in all available plasma samples pre- (day 0) and post-vaccination (days 3, 7, 10, 14, 28, 60, 90, 180 and 365). To do so, the plaque reduction neutralization assay (Stefano, I., H.K. Sato, C.S. Pannuti, T.M. Omoto, G. Mann, M.S. Freire, A.M. Yamamura, P.F. Vasconcelos, G.W. Oselka, L.W. Weckx, et al. 1999. Vaccine. 17:1042–1046) was performed in Dr. Rafi Ahmed's laboratory. N/D, Not determined.
Supplemental Table 3. *In vivo* vaccination and *in vitro* primary immune response against YF17D yield similar gene signatures

<table>
<thead>
<tr>
<th>Whole blood Montreal</th>
<th>Whole blood Lausanne</th>
<th>VaxDesign</th>
</tr>
</thead>
<tbody>
<tr>
<td>BACH1</td>
<td>CBFA2T2</td>
<td></td>
</tr>
<tr>
<td>BACH2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEBPA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEBPB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEBPA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CUTL1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2F4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETS2</td>
<td></td>
<td>FOXF2</td>
</tr>
<tr>
<td>ETS2</td>
<td></td>
<td>FOXO1A</td>
</tr>
<tr>
<td>FOXO3</td>
<td></td>
<td>FO XO3</td>
</tr>
<tr>
<td>GATA1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GATA6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSF1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF1</td>
<td>IRF1</td>
<td>IRF1</td>
</tr>
<tr>
<td>IRF2</td>
<td>IRF2</td>
<td>IRF2</td>
</tr>
<tr>
<td>IRF7</td>
<td>IRF7</td>
<td>IRF7</td>
</tr>
<tr>
<td>IRF8</td>
<td>IRF8</td>
<td>IRF8</td>
</tr>
<tr>
<td>JUN</td>
<td>JUN</td>
<td>JUN</td>
</tr>
<tr>
<td>LMO2</td>
<td>MLLT7</td>
<td>MLLT7</td>
</tr>
<tr>
<td>MLLT7</td>
<td>POU2F1</td>
<td></td>
</tr>
<tr>
<td>MLLT7</td>
<td>POU6F1</td>
<td></td>
</tr>
<tr>
<td>MLLT7</td>
<td>REL</td>
<td></td>
</tr>
<tr>
<td>MLLT7</td>
<td>RORA</td>
<td></td>
</tr>
<tr>
<td>POU2F1</td>
<td>REL</td>
<td></td>
</tr>
<tr>
<td>POU6F1</td>
<td>RORA</td>
<td></td>
</tr>
<tr>
<td>SRF</td>
<td>STAT1</td>
<td>STAT1</td>
</tr>
<tr>
<td>STAT1</td>
<td>STAT1</td>
<td>STAT1</td>
</tr>
<tr>
<td>TAL1</td>
<td>TBP</td>
<td></td>
</tr>
<tr>
<td>TFAP4</td>
<td>TFDP1</td>
<td>VDR</td>
</tr>
<tr>
<td>VSX1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comparison of the transcription factors (with predicted target genes showing a specific modulation) identified by ICA and gene set enrichment analysis. Whole blood (PaxGene tubes) pre- and post-vaccination versus VaxDesign MIMIC system. Transcription factors identified in both analyses are highlighted.
### Supplemental Table 4.

In vivo vaccination and in vitro primary immune response against YF17D induce common gene sets

<table>
<thead>
<tr>
<th>Gene Set Name</th>
<th>Montreal</th>
<th>Lausanne</th>
<th>VaxDesign</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRANDVAUX_IFN_NOT_IRF3_UP</td>
<td>1.31E-012</td>
<td>4.87E-015</td>
<td>1.09E-009</td>
</tr>
<tr>
<td>RADAeva_IFNA_UP</td>
<td>1.33E-016</td>
<td>1.30E-018</td>
<td>6.73E-015</td>
</tr>
<tr>
<td>WIELAND_HEPATITIS_B_INDUCED</td>
<td>2.58E-012</td>
<td>4.78E-009</td>
<td>6.11E-011</td>
</tr>
<tr>
<td>UV-CMV_UNIQUE_HCMV_6HRS_UP</td>
<td>3.63E-009</td>
<td>4.52E-009</td>
<td>4.15E-005</td>
</tr>
<tr>
<td>CMV-UV_HCMV_6HRS_UP</td>
<td>1.01E-012</td>
<td>7.23E-014</td>
<td>2.63E-006</td>
</tr>
<tr>
<td>IFNA_UV-CMV_COMMON_HCMV_6HRS_UP</td>
<td>2.14E-015</td>
<td>1.68E-019</td>
<td>1.23E-007</td>
</tr>
<tr>
<td>GRANDVAUX_IRF3_UP</td>
<td>2.16E-006</td>
<td>5.41E-007</td>
<td>3.13E-005</td>
</tr>
<tr>
<td>DER_IFNB_UP</td>
<td>5.67E-017</td>
<td>1.31E-016</td>
<td>2.70E-008</td>
</tr>
<tr>
<td>DER_IFNG_UP</td>
<td>1.01E-007</td>
<td>6.10E-009</td>
<td>2.59E-007</td>
</tr>
<tr>
<td>BECKER_IFN_INDUCIBLE_SUBSET_1</td>
<td>2.64E-005</td>
<td>2.17E-005</td>
<td>0.000167804</td>
</tr>
<tr>
<td>DER_IFNA_UP</td>
<td>1.17E-016</td>
<td>9.46E-017</td>
<td>9.18E-009</td>
</tr>
<tr>
<td>CMV_HCMV_TIMECOURSE_12HRS_UP</td>
<td>1.18E-010</td>
<td>1.28E-012</td>
<td>8.71E-008</td>
</tr>
<tr>
<td>HPV31_DN</td>
<td>6.18E-005</td>
<td>0.000621834</td>
<td>9.46E-006</td>
</tr>
<tr>
<td>IFN-alpha_NL_HCC_UP</td>
<td>1.10E-007</td>
<td>2.33E-011</td>
<td>6.51E-007</td>
</tr>
<tr>
<td>IFN-alpha_NL_UP</td>
<td>2.54E-010</td>
<td>1.04E-013</td>
<td>3.91E-008</td>
</tr>
<tr>
<td>DAC_IFN_BLADDER_UP</td>
<td>1.07E-007</td>
<td>1.29E-008</td>
<td>7.30E-009</td>
</tr>
<tr>
<td>CMV_8HRS_UP</td>
<td>2.32E-007</td>
<td>3.45E-010</td>
<td>3.78E-006</td>
</tr>
<tr>
<td>IFNA_HCMV_6HRS_UP</td>
<td>3.17E-026</td>
<td>6.02E-029</td>
<td>1.89E-009</td>
</tr>
<tr>
<td>CMV_ALL_UP</td>
<td>6.50E-006</td>
<td>6.09E-008</td>
<td>0.000205016</td>
</tr>
<tr>
<td>REOVIRUS_HEK293_UP</td>
<td>2.17E-006</td>
<td>1.29E-008</td>
<td>2.31E-005</td>
</tr>
<tr>
<td>IFN-alpha_HCC_UP</td>
<td>1.74E-008</td>
<td>1.84E-011</td>
<td>1.23E-007</td>
</tr>
<tr>
<td>IFN_BETA_UP</td>
<td>5.28E-012</td>
<td>2.43E-010</td>
<td>4.40E-006</td>
</tr>
<tr>
<td>IFN_ALPHA_UP</td>
<td>1.31E-012</td>
<td>1.70E-012</td>
<td>8.47E-007</td>
</tr>
<tr>
<td>IFN_ANY_UP</td>
<td>3.23E-011</td>
<td>1.27E-010</td>
<td>5.30E-005</td>
</tr>
</tbody>
</table>

Common gene sets identified in the Montreal, Lausanne, and VaxDesign microarray data by ICA and gene set enrichment (fdr < 0.001) using the MSigDB c2 "curated gene sets" database.
Supplemental Table 5. Viremia following YF vaccination is variable

<table>
<thead>
<tr>
<th>Volunteer</th>
<th>Days post-vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>YF001</td>
<td>21.00</td>
</tr>
<tr>
<td>YF002</td>
<td>21.00</td>
</tr>
<tr>
<td>YF003</td>
<td>21.00</td>
</tr>
<tr>
<td>YF004</td>
<td>21.00</td>
</tr>
<tr>
<td>YF005</td>
<td>21.00</td>
</tr>
<tr>
<td>YF006</td>
<td>21.00</td>
</tr>
<tr>
<td>YF007</td>
<td>21.00</td>
</tr>
<tr>
<td>YF008</td>
<td>21.00</td>
</tr>
<tr>
<td>YF009</td>
<td>21.00</td>
</tr>
<tr>
<td>YF010</td>
<td>21.00</td>
</tr>
<tr>
<td>YF011</td>
<td>21.00</td>
</tr>
<tr>
<td>YF012</td>
<td>21.00</td>
</tr>
<tr>
<td>YF013</td>
<td>21.00</td>
</tr>
<tr>
<td>YF014</td>
<td>21.00</td>
</tr>
<tr>
<td>YF015</td>
<td>21.00</td>
</tr>
<tr>
<td>YF016</td>
<td>21.00</td>
</tr>
<tr>
<td>YF017</td>
<td>21.00</td>
</tr>
<tr>
<td>YF018</td>
<td>21.00</td>
</tr>
<tr>
<td>YF019</td>
<td>21.00</td>
</tr>
<tr>
<td>YF020</td>
<td>21.00</td>
</tr>
</tbody>
</table>

N/D Not determined. Viremia after YF17D vaccination was assessed for each volunteer by determining the number of YF17D viral particles in plasma samples obtained at day 0, 3, 7, 10 and 28. When day 28 samples were not available, day 60 samples were used instead. The method used was the TaqMan real-time PCR assay (Applied Biosystems, Foster City, CA), and was performed in Dr. Rafi Ahmed’s laboratory at the Emory Vaccine Center in Atlanta. Numbers are expressed as viral particle per milliliter of plasma. The detection limit of the assay was 21 copies per ml.